The structural basis for the pathophysiological relevance of PAl-l in cardiovascular diseases and the development of potential PAl-l inhibitors

被引:83
作者
Gils, A [1 ]
Declerck, PJ [1 ]
机构
[1] Catholic Univ Louvain, Fac Pharmaceut Sci, Lab Pharmaceut Biol & Phytopharmacol, B-3000 Louvain, Belgium
关键词
PAl-l; serpin; fibrinolysis; thrombosis;
D O I
10.1160/TH03-12-0764
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Plasminogen activator inhibitor-I (PAI-I) is an important component of the plasminogen/plasmin system as it is the main inhibitor of tissue-type and urokinase-type plasminogen activator. Consequently, PAI-I plays an important role in cardiovascular diseases (mainly through inhibition of t-PA), and in cell migration and tumor development (mainly through inhibition of u-PA and interaction with vitronectin). As a member of the serpin superfamily, PAI-I shares important structural properties with other serpins. However, PAI-I also exhibits unique conformational and functional properties. The current review provides an overview of the knowledge on PAI-I gathered,since its discovery two decades ago. We discuss (a) its structural properties of the protein and their subsequent relation to functional activities, (b) its role in a wide variety of (patho)physiological processes and (c) a number of strategies to interfere with its functional properties eventually aiming at pharmacological modulation of this risk factor.
引用
收藏
页码:425 / 437
页数:13
相关论文
共 181 条
[1]   MECHANISMS CONTRIBUTING TO THE CONFORMATIONAL AND FUNCTIONAL FLEXIBILITY OF PLASMINOGEN-ACTIVATOR INHIBITOR-1 [J].
AERTGEERTS, K ;
DEBONDT, HL ;
DERANTER, CJ ;
DECLERCK, PJ .
NATURE STRUCTURAL BIOLOGY, 1995, 2 (10) :891-897
[2]   Comparative fibrinolytic activity of front-loaded alteplase and the single-bolus mutants tenecteplase and lanoteplase during treatment of acute myocardial infarction [J].
Al-Shwaft, KA ;
de Meester, A ;
Pirenne, B ;
Col, JJ .
AMERICAN HEART JOURNAL, 2003, 145 (02) :217-225
[3]   Production of plasminogen activator inhibitor 1 by human adipose tissue - Possible link between visceral fat accumulation and vascular disease [J].
Alessi, MC ;
Peiretti, F ;
Morange, P ;
Henry, M ;
Nalbone, G ;
JuhanVague, I .
DIABETES, 1997, 46 (05) :860-867
[4]  
ANDREASEN PA, 1986, J BIOL CHEM, V261, P7644
[5]  
Andreasen PA, 1999, THROMB HAEMOSTASIS, V81, P407
[6]   Safety of the weight-adjusted dosing regimen of tenecteplase in the ASSENT-trial [J].
Angeja, BG ;
Alexander, JH ;
Chin, R ;
Li, X ;
Barron, HV ;
Armstrong, PW ;
Granger, CB ;
Van de Werf, F ;
Gibson, CM .
AMERICAN JOURNAL OF CARDIOLOGY, 2001, 88 (11) :1240-1245
[7]  
AUDENAERT AM, 1994, J BIOL CHEM, V269, P19559
[8]   The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin:: Implications for antiangiogenic strategies [J].
Bajou, K ;
Masson, V ;
Gerard, RD ;
Schmitt, PM ;
Albert, V ;
Praus, M ;
Lund, LR ;
Frandsen, TL ;
Brunner, N ;
Dano, K ;
Fusenig, NE ;
Weidle, U ;
Carmeliet, G ;
Loskutoff, D ;
Collen, D ;
Carmeliet, P ;
Foidart, JM ;
Noël, AS .
JOURNAL OF CELL BIOLOGY, 2001, 152 (04) :777-784
[9]   Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization [J].
Bajou, K ;
Noël, A ;
Gerard, RD ;
Masson, V ;
Brunner, N ;
Holst-Hansen, C ;
Skobe, M ;
Fusenig, NE ;
Carmeliet, P ;
Collen, D ;
Foidart, JM .
NATURE MEDICINE, 1998, 4 (08) :923-928
[10]  
BENNETT WF, 1991, J BIOL CHEM, V266, P5191